Please login to the form below

Not currently logged in
Email:
Password:

BMS’ Opdivo/Yervoy combination demonstrates OS benefit

Better kidney cancer symptom control reported versus sunitinib was also reported

BMSBristol-Myers Squibb has revealed results from its phase III trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).

CheckMate-214 evaluated BMS’ combination therapy versus Pfizer’s Sutent (sunitinib), the current standard of care, in RCC patients. It found an overall survival benefit across programmed death ligand 1 (PD-L1) expression levels, which is how a patient responds to anti-PD-1/L1 antibodies.

Arvin Yang, development lead, melanoma and genitourinary cancers, BMS, said: “As a leader in immuno-oncology, we are committed to improving overall survival and are encouraged by these results in patients with advanced renal cell carcinoma, whose treatment options remain limited.”

Renal cell carcinoma is the most common type of kidney cancer in adults, accounting for more than 100,000 deaths worldwide each year, with only a 12.1% five-year survival rate for those diagnosed with metastatic, or advanced kidney cancer.

Yang continued: “We continue to evaluate the potential of Opdivo plus Yervoy in this population and look forward to discussing these results with regulatory authorities.”

Patients also reported a statistically significant better kidney cancer symptom control with the combination compared to sunitinib when assessed using a valid tumour-specific patient-reported kidney cancer scale in the FKSI-19.

Through the first six months of data, when completion rates exceeded 80%, a 3-6 point difference was observed, which is considered clinically meaningful, according to BMS.

Meanwhile, BMS has been investigating this particular combination for other indications, including lung cancer, and the drug maker is hoping to see an approval in the second half of 2018.

Article by
Gemma Jones

8th November 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics